Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Carcinoma, Non-Small-Cell Lung 8Glioblastoma 7Carcinoma, Renal Cell 7Lung Neoplasms 6Colorectal Neoplasms 6Brenner Tumor 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Spinal Cord Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Colonic Neoplasms 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Octreotide 2Bevacizumab 2motesanib diphosphate 1batifiban 1Temozolomide 1Sorafenib 1Salts 1Oxaliplatin 1Leucovorin 1Immunoglobulin G 1Fluorouracil 1Fentanyl 1Everolimus 1Disulfides 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vipoma × Immunoglobulin G × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡